ROG has been the subject of a number of other research reports. Societe Generale set a CHF 190 price objective on Roche and gave the company a sell rating in a research note on Monday, January 15th. Berenberg Bank set a CHF 260 price objective on Roche and gave the company a neutral rating in a research note on Tuesday, October 24th. JPMorgan Chase & Co. restated a buy rating and set a price objective on shares of Roche in a research note on Thursday, November 2nd. Liberum Capital set a CHF 279 price objective on Roche and gave the company a buy rating in a research note on Wednesday, November 22nd. Finally, Jefferies Group set a CHF 300 price objective on Roche and gave the company a buy rating in a research note on Friday, January 5th. Four equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have given a buy rating to the company. The company currently has an average rating of Hold and a consensus price target of CHF 256.55.
Shares of Roche (ROG) opened at CHF 222.05 on Tuesday. Roche has a 12 month low of CHF 214.30 and a 12 month high of CHF 273. The firm has a market capitalization of $190,980.00 and a P/E ratio of 22.12.
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.